- Home
- RCKT
as 11-15-2024 4:00pm EST
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 1.4B | IPO Year: | N/A |
| Target Price: | $53.22 | AVG Volume (30 days): | 744.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.75 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.80 - $32.53 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 411.05% |
Latest Rocket Pharmaceuticals Inc. News
RCKT Breaking Stock News: Dive into RCKT Ticker-Specific Updates for Smart Investing
Business Wire
4 days ago
Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Association’s 2024 Late-Breaking Science Sessions
Zacks
5 days ago
Rocket Pharmaceuticals' Q3 Earnings Beat, Pipeline in Focus
Business Wire
8 days ago
Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference
Associated Press Finance
9 days ago
Rocket Pharmaceuticals: Q3 Earnings Snapshot
Business Wire
9 days ago
Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress
Simply Wall St.
9 days ago
Here's Why We're Watching Rocket Pharmaceuticals' (NASDAQ:RCKT) Cash Burn Situation
MT Newswires
a month ago
Scotiabank Initiates Rocket Pharmaceuticals at Sector Outperform With $50 Price Target
Business Wire
2 months ago
Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease
Compare RCKT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RCKT Rocket Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.